SIGA Technologies Inc. (SIGA) — 分析摘要
SIGA Technologies Inc.（SIGA）的市值为258.92百万美元，最近一年的营收同比增长了-31.8%。净利润率为24.6%。当前市盈率为12.8倍。
核心要点
- 营收同比变化-31.8%
- 净利润率24.6%
- 市盈率12.8倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，SIGA的营收增长为-31.8%，市盈率为12.8倍。
SIGA Technologies Inc. (SIGA)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
49
总部
NEW YORK, NY
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.60
股息收益率
17.54%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。